Efficacy of Amlitelimab in Adults With Moderate-to-Severe AD
The following is a summary of “Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis,” published in the November 2024 issue of Allergy and Immunology by Weidinger et al. Amlitelimab...